Boston Scientific (BSX) to Release Earnings on Wednesday

Key Points

• Earnings due Apr 22: Boston Scientific will report Q1 2026 results before the market opens on April 22, with analysts forecasting $0.793 EPS and $5.186 billion in revenue; company guidance is Q1 EPS $0.780–0.800 and FY 2026 EPS $3.430–3.490.
• Legal overhang: Multiple law firms have filed or solicited plaintiffs for securities-class-action suits — including allegations of concealed electrophysiology demand weakness — creating potential headline-driven volatility and a May 4, 2026 lead-plaintiff deadline.
• Insider sale and analyst view: CEO Michael Mahoney sold 160,901 shares in February (reducing his ownership by ~10.2%), Boston Scientific has a consensus "Moderate Buy" from analysts with an average price target of about $102.91, and institutional ownership is high (~89%).

Boston Scientific (NYSE:BSX - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect Boston Scientific to post earnings of $0.7930 per share and revenue of $5.1861 billion for the quarter. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Up 1.0%

Shares of NYSE:BSX opened at $63.82 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $94.85 billion, a PE ratio of 32.90, a price-to-earnings-growth ratio of 0.98 and a beta of 0.78. The firm's 50-day moving average is $70.34 and its two-hundred day moving average is $87.52. Boston Scientific has a 1 year low of $60.59 and a 1 year high of $109.50.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citi reaffirmed a Buy on BSX (Joanne Wuensch lowered the price target from $98 to $87 but kept the Buy), implying material upside vs. current levels. Citi Reiterates Buy rating for Boston Scientific (BSX)
• Positive Sentiment: Analyst commentary and coverage (Zacks/other outlets) highlight BSX’s strong earnings surprise history and the company’s potential to beat next quarter, a near-term catalyst for upside if results repeat. Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
• Negative Sentiment: Multiple law firms have filed or solicited clients for a securities-class-action against BSX covering purchases between July 2025 and Feb 2026, creating potential litigation risk and headline-driven volatility (lead-plaintiff deadline May 4, 2026). Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Several firms (Pomerantz, Rosen, Faruqi, Bernstein Liebhard, Gross, Glancy Prongay, Portnoy, Levi & Korsinsky) are issuing investor alerts encouraging claims/lead-plaintiff motions—amplifying the legal overhang and media coverage. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
• Negative Sentiment: Levi & Korsinsky’s alert specifically alleges alleged concealment of electrophysiology demand weaknesses — a potentially material operational allegation that could influence investor perception if substantiated. BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Alleged Concealment of Electrophysiology Demand Weaknesses

Wall Street Analyst Weigh In

A number of analysts have issued reports on BSX shares. BTIG Research reiterated a "buy" rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Evercore cut their target price on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. Robert W. Baird cut their target price on shares of Boston Scientific from $118.00 to $101.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. Finally, Sanford C. Bernstein restated an "outperform" rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $102.91.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sunbelt Securities Inc. boosted its holdings in Boston Scientific by 33.0% in the fourth quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider's stock valued at $135,000 after purchasing an additional 350 shares in the last quarter. Compound Planning Inc. boosted its holdings in Boston Scientific by 14.7% in the fourth quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider's stock valued at $1,471,000 after purchasing an additional 1,978 shares in the last quarter. Axxcess Wealth Management LLC boosted its holdings in Boston Scientific by 130.9% in the fourth quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider's stock valued at $2,703,000 after purchasing an additional 16,068 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Boston Scientific by 11.1% in the fourth quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider's stock valued at $22,238,000 after purchasing an additional 24,194 shares in the last quarter. Finally, Strive Financial Group LLC acquired a new position in Boston Scientific in the fourth quarter valued at approximately $1,499,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.